AzTrials
AzTrials

DepressionPhase 2rTMS-P50NCT01466439

Repetitive Transcranial Magnetic Stimulation (rTMS) and P50 Evoked Potential Component

A Phase 2 study testing high-frequency of repetitive transcranial magnetic stimulation (rTMS) and low frequency of repetitive transcranial magnetic stimulation (rTMS) in people with Depression and Schizophrenia, run by University Hospital, Caen at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The repetitive transcranial magnetic stimulation (rTMS) is a recent technique that has demonstrated its efficiency in both depression and schizophrenia. However if its efficiency has been recognized by the scientific community and the clinicians, its action on neurons and cerebral networks remains debated. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Depression, Schizophrenia
What is being tested?
high-frequency of repetitive transcranial magnetic stimulation (rTMS) and low frequency of repetitive transcranial magnetic stimulation (rTMS)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteFrance
Study dates
May 2011to Jun 2013
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • healthy subjects, right-handed, aged from 18 to 60 years
  • written consent
  • with social security

Who cannot join

  • pregnancy, breastfeeding
  • brain tumor or epilepsy
  • psychiatric, neurological or ear-nose-throat disorders, current or past
  • healthy subjects with psychotropic drugs or with substance abuses
  • healthy subjects with tabacco weaning
  • protected major with tutor
  • counter-indication to MRI and rTMS

Trial locations and contacts

1 site in 1 country.

France1 site
  • Caen University Hospital, department of psychiatry and explorations fonctionnelles neurologiques

    Caen

Other trials in France

About this study

Official title: Evaluation of Effect of Low and High-frequencies of Repetitive Transcranial Magnetic Stimulation (rTMS) by the Suppression of P50 Evoked Potential Component (rTMS-P50)

The repetitive transcranial magnetic stimulation (rTMS) is a recent technique that has demonstrated its efficiency in both depression and schizophrenia. However if its efficiency has been recognized by the scientific community and the clinicians, its action on neurons and cerebral networks remains debated.

In the motor regions, the different rTMS studies generally use frequencies of stimulation of 1 to 40 Hz with differential effects; the low frequencies being associated with an inhibitory effect whereas highest frequencies have rather some facilitator effects as attested by the motor responses. What is valid for the motor system is not however necessarily applicable to other cerebral regions that have different neuronal organizations. If it is easy to observe these opposite effects of rTMS on the motor system (presence or absence of movements), these potential effects on more integrated cortex involved in high level functions have not been proved.

Read more

One of the possibilities to interpret the effects of the rTMS in no-motor cerebral regions would be to study the modifications of the EEG before and after rTMS and to see if a differential effect of the high and low frequencies of stimulation exists. Up to now, the studies having coupled these two techniques have observed modifications of the brain electric activity only during some seconds to minutes after rTMS, what appears in contrast with the clinical effects observed after a long delay (several days).

The contribution of our research resides in the use of the paradigm of suppression of P50 evoked potential component before and after rTMS tested with low and high frequencies of stimulation. This paradigm consists in two identical auditory stimuli presented at a very short interval (generally 500 milliseconds), the second sound generating a P50 wave of weaker amplitude than the first or being completely abolished in healthy subjects. However, this effect that has been well studied could result from an inhibitory action due to the gabaergic interneurons on the pyramidal neurons of the cortex. Thus, the investigators hypothesize that high frequency rTMS would have a facilitator effect on temporal lobe and so would induce no suppression of the P50 after-rTMS whereas low frequency rTMS would induce an inhibitory effect marked by a greater suppression of the P50.

Methods: 30 healthy subjects (of which 16 women) will be included after written consent. They will receive after randomization 2 sessions of rTMS in cross over at 1Hz and 20Hz at 30 days interval. An EEG and a P50 evoked potential will be done before and after rTMS. The site of stimulation will be determined by neuronavigation and will correspond to the maximal activation cluster generated by a language task during functional magnetic resonance imaging. The main judgment criterion is the S2/S1 ratio of the P50. The potential secondary effects will be evaluated (UKU adapted). The secondary criteria are the comparisons before and after rTMS of EEG spectrums in the alpha, beta and gamma bands.

Being tested
high-frequency of repetitive transcranial magnetic stimulation (rTMS), low frequency of repetitive transcranial magnetic stimulation (rTMS)
Keywords
rTMS, P50, inhibitory, facilitatory, physiological process, brain changes
Medical subject headings
Depression, Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • high-frequency of repetitive transcranial magnetic stimulation (rTMS)Procedure or surgery

    frequency of stimulation of 20 Hz

  • low frequency of repetitive transcranial magnetic stimulation (rTMS)Procedure or surgery

    frequency of stimulation of 1 Hz

Study groups in NCT01466439
Study groupRoleWhat they receive
high frequency rTMSOtherNot described
Receives: Procedure: high-frequency of repetitive transcranial magnetic stimulation (rTMS)
low frequency rTMSOtherNot described
Receives: Procedure: low frequency of repetitive transcranial magnetic stimulation (rTMS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. P50 Ratio Stimulation 2/S stimulation 1

    Measured: day of stimulation (day 1)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Nov 2011 (estimated)
  2. Study startMay 2011
  3. Primary completionJun 2012
  4. Study completionJun 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01466439
Sponsor's protocol ID
09-181
Acronym
rTMS-P50
Status last verified
Jun 2013
First submitted
19 Oct 2011
Last updated
2 Apr 2026
Results posted
No
Data monitoring committee
No

Publications

  • Nathou C, Etard O, Simon G, Dollfus S. How do high- and low-frequency repetitive transcranial magnetic stimulations modulate the temporal cortex. Psychophysiology. 2015 Feb;52(2):192-8. doi: 10.1111/psyp.12323. Epub 2014 Sep 16.

    PubMed 25223883

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing high-frequency of repetitive transcranial magnetic stimulation (rTMS) and low frequency of repetitive transcranial magnetic stimulation (rTMS) in people with Depression and Schizophrenia, run by University Hospital, Caen at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

P50 Ratio Stimulation 2/S stimulation 1 (time frame: day of stimulation (day 1)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01466439, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in